PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Disease

Lymphoma, Large B Cell, Diffuse

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUL 22, 2026 · JOURNAL ARTICLE

Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.

Annals of Medicine

Retrospective multicenter study showing high response rates and 2-year survival outcomes for a high-risk CD5+ DLBCL population treated with Pola-R-CHP, with interim PET response predicting survival, but limited by small sample size, retrospective design, and short median follow-up.

PromisingLijie Yan Junqing Xu Neoplasm Staging

Reported

Sample size32

Median age63.5 years

Stage III-IV disease78.1%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support